Item 7.01. Regulation FD Disclosure.

On January 11, 2021, Seres Therapeutics, Inc. (the "Company") posted an updated corporate slide presentation in the "Investors and News" portion of its website at www.serestherapeutics.com. The slide presentation includes a summary SER-109 Phase 3 study engraftment and metabolomic study results. A copy of the slide presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K (the "Current Report").

The information in Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following Exhibit 99.1 relates to Item 7.01, and shall be deemed to be furnished, and not filed:





Exhibit
  No.        Description

99.1           Seres Therapeutics, Inc. Corporate Slide Presentation as of January
             11, 2021

104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses